Amicus Therapeutics, Inc.
Amicus Therapeutics, Inc. (FOLD) Revenue
Annual & quarterly revenue history · segment & region breakdown
FOLD · revenue · updated Jun 8, 2026
Core revenue metrics
Trailing 12 monthsAmicus Therapeutics, Inc. trailing twelve-month (TTM) revenue is $0.63B, an increase of 20.05% year-over-year from $0.63B in FY2025.
Revenue trend
2025 – 2006 · AnnualRevenue history
| Fiscal year end | Revenue | Change | Growth |
|---|---|---|---|
| 2025-12-31 | $0.63B | +$0.11B | +20.05% |
| 2024-12-31 | $0.53B | +$0.13B | +32.29% |
| 2023-12-31 | $0.40B | +$0.07B | +21.30% |
| 2022-12-31 | $0.33B | +$0.02B | +7.76% |
| 2021-12-31 | $0.31B | +$0.04B | +17.11% |
| 2020-12-31 | $0.26B | +$0.08B | +43.16% |
| 2019-12-31 | $0.18B | +$0.09B | +99.72% |
| 2018-12-31 | $0.09B | +$0.05B | +147.08% |
| 2017-12-31 | $0.04B | +$0.03B | +644.86% |
| 2016-12-31 | $0.00B | +$0.00B | — |
Compare revenue vs peers
BiotechnologyCompare FOLD revenue against listed peers. Click any row to open that company's revenue tab.
Revenue breakdown
Segment & GeographyAbout Revenue & Reporting
Revenue (also called sales, net sales, or turnover) is the total income Amicus Therapeutics, Inc. receives from its business operations before deducting any costs or expenses. It is the top line of the income statement. Unlike net income or earnings, revenue does not account for operating costs, taxes, interest, or depreciation.
Amicus Therapeutics, Inc. reports revenue on a fiscal year ending Dec 31 basis under US GAAP, denominated in USD.
Data sourced from Amicus Therapeutics, Inc.'s 10-K and 10-Q SEC filings via Financial Modeling Prep.
Frequently asked questions
FOLD revenue · 4 questionsFOLD's trailing twelve-month (TTM) revenue is $0.63B. That is an increase of 20.05% year-over-year from $0.63B in FY2025.
▸ Source: FMP · Amicus Therapeutics, Inc. SEC filings · GAAP · Amicus Therapeutics, Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 8, 2026